Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of neratinib in ERBB-mutant or EGFR-amplified solid tumors
MOH_2019-01-28_004939Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in Nonhematologic neoplasms, breast cancer, bladder cancer and 7 more (6 arms), sponsored by Puma Biotechnology, Inc. Primary endpoint: Objective response rate. Started Sep 2014; status: completed.
02
Drugs
neratinib
03
Conditions
Nonhematologic neoplasmsbreast cancerbladder cancertransitional cell carcinoma (TCC)bronchial carcinoma
Beyond the preview
Go deeper on MOH_2019-01-28_004939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-28_004939.